Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,435 shares at $20.45 ($132K) on 2025-07-28, disclosed to the SEC on 2025-07-30.
Scheduled sale ($132k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.45 | 3,185 | $65K | 49.5% |
| 2 | $20.45 | 3,185 | $65K | 49.5% |
| 3 | $21.30 | 65 | $1K | 1.1% |
| Total | $20.46 avg | 6,435 | $132K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |